AR120476A2 - METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION - Google Patents
METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATIONInfo
- Publication number
- AR120476A2 AR120476A2 ARP200103168A ARP200103168A AR120476A2 AR 120476 A2 AR120476 A2 AR 120476A2 AR P200103168 A ARP200103168 A AR P200103168A AR P200103168 A ARP200103168 A AR P200103168A AR 120476 A2 AR120476 A2 AR 120476A2
- Authority
- AR
- Argentina
- Prior art keywords
- risk
- subject
- event
- bupropion
- naltrexone
- Prior art date
Links
Abstract
La presente solicitud se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, con el propósito de reducir el riesgo de padecer desenlaces o eventos adversos cardiovasculares, lo cual incluye los eventos adversos cardiovasculares graves (MACE, major adverse carbiovascular events) en los sujetos, preferiblemente, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, que puedan tener sobrepeso o ser obesos. La presente solicitud también se refiere a composiciones, kits, usos, sistemas y métodos para utilizar naltrexona y bupropión o sus sales farmacéuticamente aceptables, en el tratamiento del sobrepeso o de la obesidad en los sujetos, con preferencia, en aquellos sujetos cuyo riesgo de sufrir desenlaces cardiovasculares adversos o MACE es mayor, en el cual el tratamiento reduce el riesgo de MACE.The present application refers to compositions, kits, uses, systems and methods for using naltrexone and bupropion or their pharmaceutically acceptable salts, with the purpose of reducing the risk of suffering cardiovascular adverse outcomes or events, which includes serious adverse cardiovascular events ( MACE, major adverse cardiovascular events) in subjects, preferably in those subjects who are at higher risk of adverse cardiovascular outcomes or MACE, who may be overweight or obese. The present application also refers to compositions, kits, uses, systems and methods for using naltrexone and bupropion or their pharmaceutically acceptable salts, in the treatment of overweight or obesity in subjects, preferably in those subjects whose risk of suffering adverse cardiovascular outcomes or MACE is greater, in which treatment reduces the risk of MACE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913216P | 2013-12-06 | 2013-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120476A2 true AR120476A2 (en) | 2022-02-16 |
Family
ID=58700129
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104531A AR098631A1 (en) | 2013-12-06 | 2014-12-05 | METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCT |
| ARP200103168A AR120476A2 (en) | 2013-12-06 | 2020-11-16 | METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104531A AR098631A1 (en) | 2013-12-06 | 2014-12-05 | METHOD FOR TREATING A SUBJECT THAT HAS A RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD FOR PREVENTING OR DELAYING THE BEGINNING OF SUCH EVENT, METHOD FOR TREATING A SUBJECT FOR OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICINAL PRODUCT |
Country Status (1)
| Country | Link |
|---|---|
| AR (2) | AR098631A1 (en) |
-
2014
- 2014-12-05 AR ARP140104531A patent/AR098631A1/en not_active Application Discontinuation
-
2020
- 2020-11-16 AR ARP200103168A patent/AR120476A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR098631A1 (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16057765A (en) | COMPOSITIONS AND METHODS TO REDUCE SERIOUS CARDIOVASCULAR ADVERSE EVENTS | |
| CL2018003588A1 (en) | Use of myostatin inhibitors and combination therapies. | |
| AR092177A1 (en) | METHODS TO TREAT OR PREVENT ASTHMA BY MANAGING AN IL-4R ANTAGONIST | |
| CR20160069A (en) | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | |
| CL2013001093A1 (en) | Tricyclic compounds that inhibit the kinase pi3 (pi3k); pharmaceutical composition that includes them; method to treat cancer; and its use for the treatment of cancer. | |
| ECSP15000223A (en) | METHODS FOR THE TREATMENT OF OVERWEIGHT AND OBESITY | |
| CL2013000063A1 (en) | A method of treating a subject comprising administering optionally deuterated n-ethyl-n-phenyl1,2-dihydroxy-4-hodroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, for the treatment of a disease autoimmune; a mixture thereof; Pharmaceutical composition and its preparation process. | |
| BR112015027282A8 (en) | liquid formulation and kit comprising fenfluramine, and uses thereof in the treatment of dravet syndrome | |
| BR112018000212A2 (en) | combined use of anti pd-1 and anti m-csf antibodies in cancer treatment | |
| CL2012000702A1 (en) | Use of an alpha-7 nicotinic acetylcholine receptor agonist for the treatment of dyskinesia associated with dopamine agonist therapy in Parkinson's disease. | |
| AR108021A1 (en) | ADJUSTMENTS OF ANTIBODY-ACTIVE PRINCIPLE (ADCS) OF KSP INHIBITORS WITH ANTI-B7H3 ANTIBODIES | |
| BR112018006039A2 (en) | adjuvant therapy with 25-hydroxyvitamin d and articles therefor | |
| BR112015029056A2 (en) | compound, and subcutaneously implantable pharmaceutical pill or tablet to treat a human suffering from endometriosis | |
| BR112015027477A8 (en) | bolus, its uses, and kit | |
| BR112015010039A2 (en) | treatment of cancer with pomalidomide in an individual with renal dysfunction | |
| DOP2017000219A (en) | FORMULATION OF COMBINATION OF THESSOPHENSIN AND BETABLOCKING | |
| BR112016023450A2 (en) | use of ctla4 compounds to achieve drug-free remission in individuals with early rheumatoid arthritis | |
| CL2017000884A1 (en) | Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery | |
| AR088764A1 (en) | METHODS FOR THE TREATMENT OF A SENSORY-MOTOR IMPEDIMENT RELATED TO THE CEREBROVASCULAR ACCIDENT WITH THE USE OF AMINOPIRIDINS | |
| AR120476A2 (en) | METHOD OF TREATING A SUBJECT WHO IS AT RISK OF SUFFERING A SERIOUS CARDIOVASCULAR EVENT; METHOD TO PREVENT OR DELAY THE START OF SAID EVENT, METHOD TO TREAT A SUBJECT DUE TO OVERWEIGHT OR OBESITY AND USE OF NALTREXONE AND BUPROPION FOR THE PREPARATION OF A MEDICATION | |
| BR112018069174A2 (en) | treatment of uremic itching | |
| BR112013027006A2 (en) | method of producing substances with supersaturated gas, transdermal delivery device thereof | |
| CO2019013940A2 (en) | Methods to reduce or prevent cardiovascular events in patients with type ii diabetes mellitus | |
| BR112018072255A2 (en) | azasteroids for tuberculosis treatment | |
| CL2009001221A1 (en) | Use of an androgen and / or a selective androgen receptor modulator to prepare a medicament for the treatment of heart failure or for slowing or arresting the progression of heart failure in a human female subject. |